个性化文献订阅>期刊> Journal of Medicinal Chemistry
 

2-Thiazolylimino/Heteroarylimino-5-arylidene-4-thiazolidinones as New Agents with SHP-2 Inhibitory Action.

  作者 Geronikaki, A.;Eleftheriou, P.;Vicini, P.;Alam, I.;Dixit, A.;Saxena, A. K.;  
  选自 期刊  Journal of Medicinal Chemistry;  卷期  2008年51-17;  页码  5221-5228  
  关联知识点  
 

[摘要]PTPN11 gene, mediates cell signaling by growth factors and cytokines via the RAS/MAP kinase pathway. Somatic mutations in PTPN11 gene account for approx. 18% of juvenile myelomonocytic leukemia (JMML) patients. Moreover, SHP-2 mutations leading to continuously active enzyme were found in more than 50% of Noonan syndrome patients and are considered to be responsible for the high tendency of these patients to juvenile leukemias and other cancer types. Recently SHP-2 became a new drug target, but till now little has been done in this field. In the present study, 17 2-thiazolylimino/heteroarylimino-5-arylidene-4-thiazolidinones divided into three series of derivs. bearing thiazole-, benzo[d]thiazole-, and benzo[d]isothiazole rings were tested for SHP-2 inhibitory activity. Most of the compds. were good SHP-2 inhibitors. Benzo[d]thiazole derivs. exhibited the best inhibitory action. Docking studies revealed that hydrophobic interactions and hydrogen bond formation stabilize enzyme-inhibitor complex.

 
      被申请数(0)  
 

[全文传递流程]

一般上传文献全文的时限在1个工作日内